Objective
Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million people lose their lives to cancer every year, making cancer a leading cause of pre-mature mortality in the world. The main hallmarks of severe eye conditions (i.e angiogenesis, inflammation and vascular permeability) play also pivotal roles in cancer, being therapeutic targets to treat both kind of diseases.
The overall goal of 3D-NEONET is the improvement of available treatments for cancer and ocular disease by enhancing drug discovery-development and delivery to targeted tissues, through advanced international co-operation between academic and non-academic partners. The interdisciplinary expertise provided by 18 partners in 7 countries encompasses among others: drug screens, ADME, toxicology, preclinical models, nanotechnology, biomaterials and clinical trials.
After the success with ongoing FP7-IAPP project 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; (www.ucd.ie/3dnet) we are assembling 3D-NEONET, this enlarged European interdisciplinary consortium that will join forces and exchange skills to enhance current therapies in oncology and ophthalmology.
The 3 global objectives of 3D-NEONET are:
1- Enhance the discovery and development of novel drugs, targets and biomarkers for ophthalmology and oncology.
2- Improve the Delivery of Therapeutics for Oncology and Ophthalmology
3- Enhancement of Research, Commercial and Clinical Trial Project Management Practices in these fields.
Through participation in the program, 3D-NEONET is the vehicle for driving synergies between academic and non-academic participants leading to increased scientific and technological excellence as well as tangible innovative outputs that will strengthen the competitiveness of both the researchers and industries of the network even beyond the lifetime of the network.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineoncologyprostate cancer
- medical and health sciencesclinical medicineoncologylung cancer
- medical and health sciencesclinical medicineoncologybreast cancer
- medical and health sciencesclinical medicineophthalmologyretinopathy
Programme(s)
Coordinator
4 Dublin
Ireland
See on map
Participants (20)
47002 Valladolid
See on map
581 83 Linkoping
See on map
D02 CX56 Dublin 2
See on map
4715-330 Braga
See on map
H91 Galway
See on map
BT7 1NN Belfast
See on map
28040 Madrid
See on map
76131 Karlsruhe
See on map
08916 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
15782 Santiago De Compostela
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
13125 Berlin
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08907 Hospitalet De Llobregat
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
34004 Palencia
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
18 Dublin
See on map
28002 Madrid
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
N91 F6PD Mullingar, Westmeath
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
A94W1K6 Blackrock Dublin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
X91 K0EK Waterford
See on map
582 16 Linkoping
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
SG8 0SS Litlington
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (1)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
73104 Oklahoma City
See on map